Randomised, double blind, placebo controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

Clarence Liu, Lance D Blumhardt

Abstract

**Objectives**—The commonly employed outcome measures on disability and relapse rates in treatment trials of relapsing-remitting multiple sclerosis have well demonstrated sensitivity to treatment effects, but their clinical interpretation is problematic. An alternative method of analysis, which is more clinically meaningful and statistically appropriate to a condition with a fluctuating disease course, uses the summary measure statistic “area under the disability/time curve (AUC)”, to estimate each patient’s total in trial morbidity experience.

**Methods**—The AUC technique was applied in an intention to treat analysis of serial disability data derived from the expanded disability status scale (EDSS), the Scripps neurologic rating scale (SNRS), and the ambulation index (AI), collected during a double blind, randomised, placebo controlled, phase III trial of subcutaneous interferon β-1a (INF-β-1a) in relapsing-remitting multiple sclerosis (PRISMS Study). The results were compared with the often quoted “conventional” end point of mean change in disability grade, uses the summary measure statistic “area under the disability/time curve (AUC).”

**Results**—EDSS data analysed by AUC normalised to baseline scores disclosed that both doses of INF-β-1a (22 or 44 µg) were superior to placebo (p= 0.008 and 0.013, respectively). In addition, the high dose (44 µg) was more beneficial than placebo using SNRS (p= 0.038) and AI data (p= 0.039). AUC analysis of SNRS scores also showed that for patients with baseline EDSS>3.5, the 44 µg (but not the 22 µg) dose was more advantageous than placebo (p=0.028).

**Conclusions**—Summary measure analysis using the AUC of serial disability/time plots, confirms and extends the results of conventional end point analysis of disability from the PRISMS Study data. AUC evaluations show that high dose INF-β-1a (44 µg three times weekly) was beneficial on all of the clinical rating scale scores used in this study. This method provides a statistically powerful and clinically meaningful assessment of treatment effects on in trial disability in patients with multiple sclerosis with fluctuating and highly heterogeneous disease courses.

(J Neurol Neurosurg Psychiatry 1999;67:451–456)

Keywords: multiple sclerosis; outcome measures; interferon β-1a

In the past 5 years, immunomodulatory therapies for relapsing-remitting multiple sclerosis have achieved a useful reduction in relapse rate, but less clear cut benefits on permanent disability, based on the outcome measures employed. These measures have been associated either with a change in rating scores from study baseline to completion, or with “confirmed progression” as defined by a certain increase in disability scores (for example, the expanded disability status scale, EDSS) at two visits 3 or 6 months apart. Interpretation of these measures is difficult, as the first end point ignores the instability and variance associated with two snapshot assessments in time, as well as the fluctuating disabilities that commonly occur in relapsing-remitting multiple sclerosis, whereas the so called confirmed progression (and its graphical depiction using Kaplan-Meier survival curves) includes an unknown number of erroneous treatment failures (that is, cases with recovery to baseline after satisfying so called progression criteria). End points which are both clinically and statistically meaningful and which incorporate the amount of disability associated with each attack into the overall disability calculations would be preferred.

One method of analysis that indexes all in trial morbidity changes is the area under the disability/time curve (AUC). This technique is appropriate for the mainly transient disability experienced early in the disease course in relapsing-remitting multiple sclerosis and should be more responsive to change as it utilises all the collected serial data. In the present study, we have reanalysed with AUCs the clinical rating scores obtained in a randomised, double blind, placebo controlled trial of interferon β-1a (INF-β-1a: Rebif®, Ares Serono) given subcutaneously in relapsing-remitting multiple sclerosis, recently published by the PRISMS (prevention of relapses and disability by interferon-beta 1a subcutaneously in multiple sclerosis) Study Group. The results are compared with a conventional method of disability analysis (2 year change in clinical rat-
### Table 1: Total cohort (n=560) disability changes as measured by (A) EDSS, (B) SNRS, and (C) AI, analysed using 2 year disability differences and AUC$^{CHANGE}$ for all visits: median (interquartile difference) and mean (SD)

<table>
<thead>
<tr>
<th></th>
<th>Two year difference</th>
<th>AUC$^{CHANGE}$ (in EDSS-years)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median Mean Median Mean</td>
<td>Median Mean Median Mean</td>
</tr>
<tr>
<td><strong>(A) EDSS:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN-β-1a 44 µg (3/week)</td>
<td>0 (1.5) +0.24 (1.13) +0.06 (1.67) +0.33 (1.63)</td>
<td></td>
</tr>
<tr>
<td>IFN-β-1a 22 µg (3/week)</td>
<td>0 (1.5) +0.23 (1.29) +0.05 (1.76) +0.36 (1.89)</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>+0.5 (1.0) +0.48 (1.27) +0.48 (1.75) +0.81 (1.95)</td>
<td></td>
</tr>
<tr>
<td><strong>(B) SNRS:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN-β-1a 44 µg (3/week)</td>
<td>-1 (10) -1.10 (8.02) +0.17 (13.12) -0.84 (11.65)</td>
<td></td>
</tr>
<tr>
<td>IFN-β-1a 22 µg (3/week)</td>
<td>0 (9.5) -1.74 (9.13) -0.25 (9.63) -1.46 (12.21)</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>-2 (7.5) -3.13 (9.10) -1.68 (11.83) -3.29 (12.59)</td>
<td></td>
</tr>
<tr>
<td><strong>(C) AI:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN-β-1a 44 µg (3/week)</td>
<td>0 (1) +0.24 (0.99) 0 (1.22) +0.25 (1.31)</td>
<td></td>
</tr>
<tr>
<td>IFN-β-1a 22 µg (3/week)</td>
<td>0 (1) +0.46 (1.25) +0.17 (0.97) +0.53 (1.60)</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>0 (1) +0.44 (1.30) +0.11 (3.05) +0.65 (2.51)</td>
<td></td>
</tr>
</tbody>
</table>

Methods

**PATIENTS**

A total of 560 patients with relapsing-remitting multiple sclerosis were enrolled and randomised to 44 µg (12 MIU) or 22 µg (6 MIU) IFN-β-1a or placebo, ad administered three times weekly by subcutaneous injection (totalling 132, 66, and 0 µg IFN-β-1a per week, respectively). Details of the patient cohort, exclusion criteria, and clinical results have been reported in an earlier publication by the PRISMS Study Group.

Patients were assessed neurologically and scored on the EDSS, Scripps neurologic rating scale (SNRS) and the ambulation index (AI) at the start of the trial and at each visit, by an examining neurologist blinded to the treatment category. In 14 centres, 316 patients had scheduled assessments carried out at 3 monthly appointments. In another six centres, additional monthly scheduled visits were performed for the first 9 months in 205 patients. In one further centre, 39 patients had scheduled monthly assessments throughout the study. Extra evaluations (n=592) were carried out at unscheduled patient initiated visits associated with relapses. Total disability data sets were achieved in 533 patients (95%).

**RESULTS**

Conventional analysis (2 year disability difference) was carried out by comparing treatment effects on the changes in EDSS, SNRS, and AI, between trial entry and completion. AUCs were calculated by two methods to obtain the AUC$^{SUM}$ and the AUC$^{CHANGE}$. For AUC$^{SUM}$, the total area under the disability/time curve throughout the trial was determined. For AUC$^{CHANGE}$, the AUC$^{SUM}$ was normalised to the baseline score by subtracting the area defined by the product of the initial rating score and the study period (see appendix). Between EDSS of 5.5 to 7.0, each 0.5 point increment was rescaled to 1.0 point to adjust for non-linearity of the EDSS.

Three types of data analyses were performed. In the initial analyses (combined data), all 7060 datapoints from the scheduled and unscheduled visits of 560 patients were included in the AUC calculations (intention to treat analysis). The trapezium rule for determining the AUC was applied throughout, as most objectively confirmed attacks had only one additional neurological assessment and the speed and timing of relapse onset and offset would be difficult to define with certainty if other techniques were employed. Secondly, separate analyses (scheduled visit data) were carried out using solely the 6468 datapoints obtained at routine appointments. Thirdly, due to the different estimated disease course characteristics and DSS score staying times of patients with DSS<3 and DSS>4 in natural history series, analyses of subjects classified by baseline EDSS<3.5 (n=466) or EDSS>3.5 (n=94) were attained.

**STATISTICS**

For both conventional and AUC data, an analysis of variance (ANOVA) model was employed with factors for treatment and centre. One degree of freedom contrasts from the ANOVA model were used to compare the treatment groups in a pairwise fashion. As there was a strong effect of baseline entry scores, all further analyses of AUC$^{SUM}$ were carried out with baseline disability (EDSS, SNRS, or AI) as a covariant. ANOVAs on the ranks (Kruskal-Wallis tests) were performed to determine consistency of results and validity of the parametric (ANOVA) conclusions. As our data were not normally distributed (Shapiro-Wilk W test), p values on treatment comparisons were obtained from ANOVAs on the ranks. Mean estimates with 95% confidence intervals (95% CIs) were also calculated to compare treatment effects with placebo.

**RESULTS**

**TOTAL COHORT ANALYSIS WITH COMBINED DATA**

"2 year EDSS difference" demonstrated significant benefits favouring the 22 µg dose (p=0.026) and a tendency in favour of 44 µg (p=0.052) over placebo. AUC$^{SUM}$ calculations similarly showed that 22 µg IFN-β-1a was beneficial compared with placebo (p=0.046). Although the size of the treatment effect was similar, significance was not reached with the 44 µg dose (p=0.064).

The median AUC$^{CHANGE}$ was +0.06, +0.05, and +0.48 EDSS-year for 44 µg, 22 µg IFN-β-1a, and placebo, respectively (table 1 A). Both doses conferred significant advantages
There were no significant group differences for either the “2 year AI difference”, or AI AUC\textsuperscript{CHANGE}. On AUC\textsuperscript{CHANGE}, the 44 µg dose (median of 0 AI-year) was significantly superior to placebo (median worsening of +0.11 AI-year) (p=0.039) with a mean benefit of −0.4 AI-year (95% CI -0.7 to -0.1) (table 1 C, fig 1 F).

### TOTAL COHORT ANALYSES WITH SCHEDULED VISIT DATA

Utilising data from scheduled visits only, AUC\textsuperscript{SUM} analysis on EDSS scores disclosed a trend favouring 22 µg IFN-β-1a over placebo (p=0.058). AUC\textsuperscript{CHANGE} calculations showed that on EDSS scores, there were significant benefits of both doses over placebo (p=0.024 and 0.014 for 44 µg and 22 µg, respectively). For SNRS and AI data, treatment with IFN-β-1a 44 µg was also superior to placebo.

### SUBGROUP ANALYSES

#### EDSS

For patients with entry EDSS<3.5, treatment comparisons showed 22 µg to be better than placebo, for both “2 year EDSS difference” (p=0.016) and AUC\textsuperscript{SUM} analyses (p=0.043). Using AUC\textsuperscript{CHANGE}, there were significant effects in favour of both treatment doses compared with placebo (p=0.036 and 0.016 for 44 µg and 22 µg IFN-β-1a), with estimated benefits of −0.4 and −0.5 EDSS-year, respectively (95% CI -0.8 to 0; −0.8 to −0.1) (table 2 A, fig 2 A-B).

For patients with baseline EDSS>3.5, neither conventional “2 year EDSS difference”, nor AUC analyses, showed significant differences between treatment arms, although over placebo (p=0.013 and 0.008 for 44 µg and 22 µg IFN-β-1a, respectively), with an estimated treatment effect of −0.5 EDSS-year for each dose (95% CI −0.9 to −0.1 and −0.8 to −0.1, respectively) (fig 1 A-B).

#### SNRS

There were no significant group differences in efficacy based on either “2 year SNRS difference”, or AUC\textsuperscript{SUM} analysis. With AUC\textsuperscript{CHANGE}, the 44 µg treatment arm improved by a median of +0.17 SNRS-year compared to deteriorations of −0.25 and −1.68 SNRS-year for the 22 µg dose and placebo cohorts, respectively (table 1 B). There were significant effects in favour of 44 µg IFN-β-1a over placebo (p= 0.036), with an estimated mean benefit of +2.5 SNRS-year (95% CI +0.1 to +4.9) (fig 1 C-D).

#### AI

There were no significant group differences for either the “2 year AI difference”, or AI AUC\textsuperscript{CHANGE}. On AUC\textsuperscript{CHANGE}, the 44 µg dose (median of 0 AI-year) was significantly superior to placebo (median worsening of +0.11 AI-year) (p=0.039) with a mean benefit of −0.4 AI-year (95% CI -0.7 to -0.1) (table 1 C, fig 1 F).

![Figure 1. AUC\textsuperscript{CHANGE} data obtained on total visits with intention to treat analysis for the entire cohort (n=560). AUC\textsuperscript{CHANGE} EDSS: (A) basic statistics and (B) treatment comparisons in EDSS-years. AUC\textsuperscript{CHANGE} SNRS: (C) basic statistics and (D) treatment comparisons in SNRS-years. AUC\textsuperscript{CHANGE} AI: (E) basic statistics and (F) treatment comparisons in AI-years. (Basic statistics: histogram=group mean, horizontal bar=median, vertical line=interquartile range. Treatment comparisons: histogram=estimated mean, vertical line=95% CI, p value from ANOVA on ranks).](http://jnnp.bmj.com/10.1136/jnnp.67.4.451/fig1.png)
AUC\textsubscript{CHANGE} showed an estimated mean benefit for the 44 µg dose over placebo of −1.0 EDSS-year (95% CI −1.9 to 0) (fig 2 A-B).

SNRS
For patients with entry EDSS ≤3.5, neither “2 year SNRS difference”, AUC\textsubscript{SUM}, nor AUC\textsubscript{CHANGE} showed any significant distinctions between treatment arms (table 2 B, fig 2 C-D).

For patients with a baseline EDSS >3.5, there was a significant effect in favour of the 44 µg dose over placebo using conventional “2 year SNRS difference” (p=0.016). AUC\textsubscript{SUM} did not show differences between treatment arms. AUC\textsubscript{CHANGE} confirmed significant effects of 44 µg IFNβ-1a versus placebo (p=0.028) with a mean benefit of +9.0 SNRS-years (95% CI +2.9 to +15.1) (fig 2 C-D).

AI
Neither “2 year AI difference”, AUC\textsubscript{SUM}, nor AUC\textsubscript{CHANGE} showed any significant treatment effects over placebo for either subgroup (table 2 C, fig 2 E-F). However, for AUC\textsubscript{CHANGE}, the 44 µg dose conferred an estimated mean saving of −0.9 AI-year over placebo (95% CI −1.6 to −0.1).

**Discussion**
Whereas it is generally agreed that the primary outcome in phase III immunomodulatory trials in relapsing-remitting multiple sclerosis must be clinical,\textsuperscript{19–21} commonly employed end points associated with both disability and relapse assessment can be difficult to define and interpret.\textsuperscript{8–14} Meaningful clinical milestones, such as the conversion to secondary progression,\textsuperscript{18–19} are not realistic end points for relapsing-remitting multiple sclerosis cohorts within relatively short study periods of 2 to 3 years. Currently available clinical rating scales are variously flawed,\textsuperscript{20–22} with the EDSS being the most criticised.\textsuperscript{11–14} Other scales (including SNRS and AI) have been less thoroughly evaluated.\textsuperscript{21} We have previously proposed that the AUC summary measure statistic may solve some of these problems in a clinically meaningful way by indexing and accounting for the total morbidity change experienced by patients during the course of a trial.\textsuperscript{8}

In this paper, we have analysed data from the PRISMS trial using two AUC methods, AUC\textsubscript{SUM} and AUC\textsubscript{CHANGE}. AUC\textsubscript{SUM} sums the total disability data serially over the study period and data independence is assured (the independence is lost in analyses involving any change in disability scores as each data point is influenced by its preceding values). However, it would be expected to be insensitive to small changes in short trials if there were a large disability range in the cohort at baseline. On the other hand, AUC\textsubscript{CHANGE} obtained by normalising the AUC\textsubscript{SUM} value to the baseline rating is sensitive to in trial changes and has been previously utilised in a neurorehabilitation pilot study.\textsuperscript{20} However, neurological improvements and deteriorations may cancel and the technique is susceptible to unstable scores at trial entry, a problem partly resolved by ensuring a stable run in period.

In the present study, comparison of the two AUC techniques showed that AUC\textsubscript{SUM} essentially confirmed the “2 year disability difference” analysis (treatment benefit over placebo for EDSS, but not for SNRS or AI data) without improved responsiveness. This can be attributed to the small in study changes relative to the wide range of disability (EDSS 0–5) at baseline. By contrast, the increased sensitivity of AUC\textsubscript{CHANGE} for detecting positive therapeutic effects not only showed savings in terms of EDSS-years for both IFNβ-1a doses compared with placebo, but also significant beneficial effects in favour of the high dose (44 µg three times weekly), using SNRS and AI data.

AUC analysis has several advantages over conventional techniques for this type of study. The method can be applied to any clinical rat-
Interferon-β-1a in relapsing-remitting multiple sclerosis analysed by disability/time curves

CL and LDB were investigators in the PRISMS study. Thanks are due to Florilene Dupont and Melvin Olsen of Ares Serono for help in data analysis.

Appendix

AUC CHANGE: This is the summation of the total areas (including baseline) under the curve between each pair of consecutive scores given by the trapezium rule. If disability scores \(y_0, y_1, y_2, \ldots, y_n\) are plotted versus their times of assessment \(t_0, t_1, t_2, \ldots, t_n\), totalling \(n+1\) measurements \(y\), at times \(t_i\) (from 0, 1, 2, \ldots, \(n\)), then

\[
AUC_{\text{CHANGE}} = \frac{1}{2} \sum_{i=0}^{n-1} (t_i-t_{i+1})(y_i-y_{i+1})
\]

AUC CHANGE: This is the difference between the areas summated by AUC CHANGE and the product of the baseline disability score \(y_i\) and the total time of study \(t_i\), hence

\[
AUC_{\text{CHANGE}} = AUC_{\text{SUM}} - \sum_{i=0}^{n-1} y_i t_i
\]
